Do I need a prescription for Dopamine 200mg/50ml solution for infusion pre-filled syringes?

Dopamine 200mg/50ml solution for infusion pre-filled syringes is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Dopamine 200mg/50ml solution for infusion pre-filled syringes?

Dopamine 200mg/50ml solution for infusion pre-filled syringes is the generic name. It is available under brand names including: Dopamine 200mg/50ml solution for infusion pre-filled syringes. (Source: NHS dm+d — Actual Medicinal Products)

Dopamine 200mg/50ml solution for infusion pre-filled syringes

Prescription only

Requires a prescription from a doctor or prescriber

Infusion

200mg/50ml

Other

Oral liquids

One of the catecholamine neurotransmitters in the brain.

Active ingredients:

Dopamine

ATC classificationBrowse ATC index

International classification by the WHO, grouping medicines by the organ system they act on

ATC C01CA04

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Dopamine

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Dopamine

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Dopamine

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Dopamine

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Dopamine on the MHRA register

Dopamine 200mg/50ml solution for infusion pre-filled syringes

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Therapeutically similar medicines

10 similarShow details

Adrenaline (base) 2mg/100microlitres nasal spray unit dose

Spray

2mg

Same therapeutic group

Isoprenaline hydrochloride 200micrograms/1ml solution for infusion ampoules

Infusion

1ml

Same therapeutic group

Noradrenaline (base) 250micrograms/50ml solution for injection vials

Injection

50ml

Same therapeutic group

Isoprenaline hydrochloride 1mg/5ml solution for infusion ampoules

Infusion

1mg/5ml

Same therapeutic group

Dopamine 45mg/30ml solution for infusion vials

Infusion

45mg/30ml

Same therapeutic group

Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.

Clinical guidelines and formulary information

British National Formulary

Dopamine

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(13)

Parkinson's disease in adults (NG71)

NG71

NICE guideline

Updated Jul 2017

Parkinson's disease (QS164)

QS164

Quality standard

Updated Feb 2018

Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

HST26

Highly specialised technology

Updated Apr 2023

Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms (TA934)

TA934

Technology appraisal

Updated Nov 2023

MRI-guided focused ultrasound subthalamotomy for treating Parkinson's (HTG734)

HTG734

Guidance

Updated Dec 2024

MRI-guided focused ultrasound thalamotomy for treating moderate to severe tremor in Parkinson's (HTG733)

HTG733

Guidance

Updated Dec 2024

Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)

ESNM67

Evidence summary

Updated Dec 2015

Acute kidney injury: prevention, detection and management (NG148)

NG148

NICE guideline

Updated Oct 2024

Fertility problems: assessment and treatment (CG156)

CG156

Clinical guideline

Updated Sept 2017

Path Finder for freezing of gait in people with Parkinson's disease (MIB170)

MIB170

Guidance

Updated Jan 2019

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

TA292

Technology appraisal

Updated Jul 2013

Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

ESUOM18

Evidence summary

Updated Sept 2014

Schizophrenia: lurasidone (ESNM48)

ESNM48

Evidence summary

Updated Sept 2014

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Dopamine

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

22310111000001101

dm+d ID

22310111000001101

VTM (Virtual Therapeutic Moiety)

775687004

VMP (Virtual Medicinal Product)

22310111000001101

International identifiers

ATC code — Anatomical Therapeutic Chemical (WHO)

C01CA04

Browse tools

dm+d Browser

NHSBSA medicines dictionary lookup

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

2 found

Half-life

2 minutes

Mechanism

Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a…

Food interactions

None known

Human targets

16 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Dopamine is rapidly absorbed from the small intestine.

Half-life

2 minutes

2 minutes

Protein binding

No information currently available on protein binding.

Metabolism

Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA).…

Elimination

80%

It has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid.
A…

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.

Properties:

solid

Avg. mass: 153.18 Da

DrugBank indication

For the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure

Also known as(109)

2-(3,4-dihydroxyphenyl)ethylamine

3-Hydroxytyramine

3,4-Dihydroxyphenethylamine

4-(2-aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-aminoethyl)catechol

4-(2-aminoethyl)pyrocatechol

Dopamina

Dosage forms(53)

Injection, solution (Intravenous) — 200 mg/5ml

Injection (Intravenous)

Injection, solution, concentrate (Intravenous) — 200 mg/5ml

Solution — 40 mg/mL

Solution — 200 mg/5ml

Injection, solution, concentrate (Intravenous) — 40 mg/ml

Solution (Intravenous) — 200 mg

Solution (Intravenous) — 40 mg

Molecular properties(19)

Drug interactions(1304)

Known interactions with other medications. Always consult a healthcare professional.

Hyaluronidase (ovine)

Unknown severity

DB00070

The risk or severity of adverse effects can be increased when Hyaluronidase (ovine) is combined with Dopamine.

Check this interaction

Hyaluronidase (human recombinant)

Unknown severity

DB06205

The risk or severity of adverse effects can be increased when Hyaluronidase (human recombinant) is combined with Dopamine.

Check this interaction

Hyaluronidase

Unknown severity

DB14740

The risk or severity of adverse effects can be increased when Hyaluronidase is combined with Dopamine.

Check this interaction

Valsartan

Moderate

DB00177

Dopamine may decrease the antihypertensive activities of Valsartan.

Check this interaction

Ramipril

Moderate

DB00178

Dopamine may decrease the antihypertensive activities of Ramipril.

Check this interaction

Esmolol

Moderate

DB00187

Dopamine may decrease the antihypertensive activities of Esmolol.

Check this interaction

Betaxolol

Moderate

DB00195

Dopamine may decrease the antihypertensive activities of Betaxolol.

Check this interaction

Remikiren

Moderate

DB00212

Dopamine may decrease the antihypertensive activities of Remikiren.

Check this interaction

Guanadrel

Moderate

DB00226

Dopamine may decrease the antihypertensive activities of Guanadrel.

Check this interaction

Olmesartan

Moderate

DB00275

Dopamine may decrease the antihypertensive activities of Olmesartan.

Check this interaction

Atenolol

Moderate

DB00335

Dopamine may decrease the antihypertensive activities of Atenolol.

Check this interaction

Diltiazem

Moderate

DB00343

Dopamine may decrease the antihypertensive activities of Diltiazem.

Check this interaction

Minoxidil

Moderate

DB00350

Dopamine may decrease the antihypertensive activities of Minoxidil.

Check this interaction

Treprostinil

Moderate

DB00374

Dopamine may decrease the antihypertensive activities of Treprostinil.

Check this interaction

Amlodipine

Moderate

DB00381

Dopamine may decrease the antihypertensive activities of Amlodipine.

Check this interaction

Nimodipine

Moderate

DB00393

Dopamine may decrease the antihypertensive activities of Nimodipine.

Check this interaction

Trandolapril

Moderate

DB00519

Dopamine may decrease the antihypertensive activities of Trandolapril.

Check this interaction

Lercanidipine

Moderate

DB00528

Dopamine may decrease the antihypertensive activities of Lercanidipine.

Check this interaction

Benazepril

Moderate

DB00542

Dopamine may decrease the antihypertensive activities of Benazepril.

Check this interaction

Bosentan

Moderate

DB00559

Dopamine may decrease the antihypertensive activities of Bosentan.

Check this interaction

Enalapril

Moderate

DB00584

Dopamine may decrease the antihypertensive activities of Enalapril.

Check this interaction

Candoxatril

Moderate

DB00616

Dopamine may decrease the antihypertensive activities of Candoxatril.

Check this interaction

Nicardipine

Moderate

DB00622

Dopamine may decrease the antihypertensive activities of Nicardipine.

Check this interaction

Losartan

Moderate

DB00678

Dopamine may decrease the antihypertensive activities of Losartan.

Check this interaction

Moexipril

Moderate

DB00691

Dopamine may decrease the antihypertensive activities of Moexipril.

Check this interaction

Nitroglycerin

Moderate

DB00727

Dopamine may decrease the antihypertensive activities of Nitroglycerin.

Check this interaction

Metyrosine

Moderate

DB00765

Dopamine may decrease the antihypertensive activities of Metyrosine.

Check this interaction

Cryptenamine

Moderate

DB00785

Dopamine may decrease the antihypertensive activities of Cryptenamine.

Check this interaction

Candesartan cilexetil

Moderate

DB00796

Dopamine may decrease the antihypertensive activities of Candesartan cilexetil.

Check this interaction

Alprenolol

Moderate

DB00866

Dopamine may decrease the antihypertensive activities of Alprenolol.

Check this interaction

Eprosartan

Moderate

DB00876

Dopamine may decrease the antihypertensive activities of Eprosartan.

Check this interaction

Quinapril

Moderate

DB00881

Dopamine may decrease the antihypertensive activities of Quinapril.

Check this interaction

Telmisartan

Moderate

DB00966

Dopamine may decrease the antihypertensive activities of Telmisartan.

Check this interaction

Felodipine

Moderate

DB01023

Dopamine may decrease the antihypertensive activities of Felodipine.

Check this interaction

Irbesartan

Moderate

DB01029

Dopamine may decrease the antihypertensive activities of Irbesartan.

Check this interaction

Nitrendipine

Moderate

DB01054

Dopamine may decrease the antihypertensive activities of Nitrendipine.

Check this interaction

Deserpidine

Moderate

DB01089

Dopamine may decrease the antihypertensive activities of Deserpidine.

Check this interaction

Pentolinium

Moderate

DB01090

Dopamine may decrease the antihypertensive activities of Pentolinium.

Check this interaction

Trimethaphan

Moderate

DB01116

Dopamine may decrease the antihypertensive activities of Trimethaphan.

Check this interaction

Carvedilol

Moderate

DB01136

Dopamine may decrease the antihypertensive activities of Carvedilol.

Check this interaction

Bretylium

Moderate

DB01158

Dopamine may decrease the antihypertensive activities of Bretylium.

Check this interaction

Terazosin

Moderate

DB01162

Dopamine may decrease the antihypertensive activities of Terazosin.

Check this interaction

Captopril

Moderate

DB01197

Dopamine may decrease the antihypertensive activities of Captopril.

Check this interaction

Bepridil

Moderate

DB01244

Dopamine may decrease the antihypertensive activities of Bepridil.

Check this interaction

Bevantolol

Moderate

DB01295

Dopamine may decrease the antihypertensive activities of Bevantolol.

Check this interaction

Practolol

Moderate

DB01297

Dopamine may decrease the antihypertensive activities of Practolol.

Check this interaction

Cilazapril

Moderate

DB01340

Dopamine may decrease the antihypertensive activities of Cilazapril.

Check this interaction

Saprisartan

Moderate

DB01347

Dopamine may decrease the antihypertensive activities of Saprisartan.

Check this interaction

Spirapril

Moderate

DB01348

Dopamine may decrease the antihypertensive activities of Spirapril.

Check this interaction

Mibefradil

Moderate

DB01388

Dopamine may decrease the antihypertensive activities of Mibefradil.

Check this interaction

Showing 50 of 1304 interactions

Toxicity & overdose

LD₅₀ oral mice = 1460 mg/kg, LD₅₀ oral rats = 1780 mg/kg. Spasm or closing of eyelids, nausea, vomiting, cardiac arrhythmias, involuntary movements of the body including the face, tongue, arms, hand, head, and upper body; hypotension, haemolytic anaemia, urinary retention, duodenal ulcer, sialorrhea, ataxia, abdominal pain, dry mouth, nightmares, tachypnoea, bruxism, confusion, and insomnia.

How it works

Mechanism of action

Dopamine is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings. In the brain, dopamine acts as an agonist to the five dopamine receptor subtypes (D1, D2, D3, D4, D5).

Pharmacodynamics

Dopamine is a natural catecholamine formed by the decarboxylation of 3,4-dihydroxyphenylalanine (DOPA). It is a precursor to norepinephrine in noradrenergic nerves and is also a neurotransmitter in certain areas of the central nervous system, especially in the nigrostriatal tract, and in a few peripheral sympathetic nerves. Dopamine produces positive chronotropic and inotropic effects on the myocardium, resulting in increased heart rate and cardiac contractility. This is accomplished directly by exerting an agonist action on beta-adrenoceptors and indirectly by causing release of norepinephrine from storage sites in sympathetic nerve endings.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Dopamine is rapidly absorbed from the small intestine.

Half-life

2 minutes

Protein binding

No information currently available on protein binding.

Metabolism

Biotransformation of dopamine proceeds rapidly to yield the principal excretion products, 3-4-dihydroxy-phenylacetic acid (DOPAC) and 3-methoxy-4-hydroxy-phenylacetic acid (homovanillic acid, HVA).

Route of elimination

It has been reported that about 80% of the drug is excreted in the urine within 24 hours, primarily as HVA and its sulfate and glucuronide conjugates and as 3,4-dihydroxyphenylacetic acid.
A very small portion is excreted unchanged.

Drug targets(16)

Proteins and enzymes this drug interacts with in the body

D(2) dopamine receptor

BE0000756

DRD2

agonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase .
PMID:21645528
Positively regulates postnatal regression of retinal hyaloid vessels via suppression of VEGFR2/KDR activity, downstream of OPN5 (By similarity)

D(1A) dopamine receptor

BE0000020

DRD1

agonist

Specific functionarrestin family protein binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

D(1B) dopamine receptor

BE0000145

DRD5

agonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase

D(3) dopamine receptor

BE0000581

DRD3

agonist

Specific functiondopamine neurotransmitter receptor activity, coupled via Gi/Go

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation

D(4) dopamine receptor

BE0000389

DRD4

agonist

Specific functiondopamine binding

Cellular location

Cell membrane

General function & pharmacology

Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Activated by dopamine, but also by epinephrine and norepinephrine, and by numerous synthetic agonists and drugs .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:9003072

Agonist binding triggers signaling via G proteins that inhibit adenylyl cyclase .
PMID:16423344 PMID:27659709 PMID:29051383 PMID:7512953 PMID:7643093

Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity)

Metabolizing enzymes(4)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

DBHDopamine beta-hydroxylase

substrate

MAOAAmine oxidase [flavin-containing] A

substrate

MAOBAmine oxidase [flavin-containing] B

substrate

COMTCatechol O-methyltransferase

substrate

Transporters(5)

Proteins that transport this drug across cell membranes

Solute carrier family 22 member 2

BE0003647

SLC22A2

substrate

inhibitor

Specific functionacetylcholine transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics .
PMID:9260930 PMID:9687576
Functions as a Na(+)-independent, bidirectional uniporter .
PMID:21128598 PMID:9687576
Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient .
PMID:15212162 PMID:9260930 PMID:9687576

However, may also engage electroneutral cation exchange when saturating concentrations of cation substrates are reached (By similarity). Predominantly expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow .
PMID:15783073
Implicated in monoamine neurotransmitters uptake such as histamine, dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, serotonin and tyramine, thereby supporting a physiological role in the central nervous system by regulating interstitial concentrations of neurotransmitters .
PMID:16581093 PMID:17460754 PMID:9687576

Also capable of transporting dopaminergic neuromodulators cyclo(his-pro), salsolinol and N-methyl-salsolinol, thereby involved in the maintenance of dopaminergic cell integrity in the central nervous system .
PMID:17460754
Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium .
PMID:15817714
Also transports guanidine and endogenous monoamines such as vitamin B1/thiamine, creatinine and N-1-methylnicotinamide (NMN) .
PMID:12089365 PMID:15212162 PMID:17072098 PMID:24961373 PMID:9260930

Mediates the uptake and efflux of quaternary ammonium compound choline .
PMID:9260930
Mediates the bidirectional transport of polyamine agmatine and the uptake of polyamines putrescine and spermidine .
PMID:12538837 PMID:21128598
Able to transport non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) .
PMID:11907186
Also involved in the uptake of xenobiotic 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) .
PMID:12395288 PMID:16394027
May contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

Solute carrier family 22 member 1

BE0003648

SLC22A1

substrate

Specific function(R)-carnitine transmembrane transporter activity

Cellular location

Basolateral cell membrane

General function & pharmacology

Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics .
PMID:11388889 PMID:11408531 PMID:12439218 PMID:12719534 PMID:15389554 PMID:16263091 PMID:16272756 PMID:16581093 PMID:19536068 PMID:21128598 PMID:23680637 PMID:24961373 PMID:34040533 PMID:9187257 PMID:9260930 PMID:9655880

Functions as a pH- and Na(+)-independent, bidirectional transporter (By similarity). Cation cellular uptake or release is driven by the electrochemical potential (i.e. membrane potential and concentration gradient) and substrate selectivity (By similarity). Hydrophobicity is a major requirement for recognition in polyvalent substrates and inhibitors (By similarity).

Primarily expressed at the basolateral membrane of hepatocytes and proximal tubules and involved in the uptake and disposition of cationic compounds by hepatic and renal clearance from the blood flow (By similarity). Most likely functions as an uptake carrier in enterocytes contributing to the intestinal elimination of organic cations from the systemic circulation .
PMID:16263091
Transports endogenous monoamines such as N-1-methylnicotinamide (NMN), guanidine, histamine, neurotransmitters dopamine, serotonin and adrenaline .
PMID:12439218 PMID:24961373 PMID:35469921 PMID:9260930

Also transports natural polyamines such as spermidine, agmatine and putrescine at low affinity, but relatively high turnover .
PMID:21128598
Involved in the hepatic uptake of vitamin B1/thiamine, hence regulating hepatic lipid and energy metabolism .
PMID:24961373
Mediates the bidirectional transport of acetylcholine (ACh) at the apical membrane of ciliated cell in airway epithelium, thereby playing a role in luminal release of ACh from bronchial epithelium .
PMID:15817714
Transports dopaminergic neuromodulators cyclo(his-pro) and salsolinol with lower efficency .
PMID:17460754
Also capable of transporting non-amine endogenous compounds such as prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) .
PMID:11907186
May contribute to the transport of cationic compounds in testes across the blood-testis-barrier (Probable). Also involved in the uptake of xenobiotics tributylmethylammonium (TBuMA), quinidine, N-methyl-quinine (NMQ), N-methyl-quinidine (NMQD) N-(4,4-azo-n-pentyl)-quinuclidine (APQ), azidoprocainamide methoiodide (AMP), N-(4,4-azo-n-pentyl)-21-deoxyajmalinium (APDA) and 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP) PMID:11408531 PMID:15389554 PMID:35469921 PMID:9260930

Solute carrier family 22 member 3

BE0003650

SLC22A3

inhibitor

Specific functionmonoamine transmembrane transporter activity

Cellular location

Cell membrane

General function & pharmacology

Electrogenic voltage-dependent transporter that mediates the transport of a variety of organic cations such as endogenous bioactive amines, cationic drugs and xenobiotics .
PMID:10196521 PMID:10966924 PMID:12538837 PMID:17460754 PMID:20858707

Cation cellular uptake or release is driven by the electrochemical potential, i.e. membrane potential and concentration gradient .
PMID:10966924
Functions as a Na(+)- and Cl(-)-independent, bidirectional uniporter .
PMID:12538837
Implicated in monoamine neurotransmitters uptake such as dopamine, adrenaline/epinephrine, noradrenaline/norepinephrine, histamine, serotonin and tyramine, thereby supporting a role in homeostatic regulation of aminergic neurotransmission in the brain .
PMID:10196521 PMID:16581093 PMID:20858707

Transports dopaminergic neuromodulators cyclo(his-pro) and salsolinol with low efficiency .
PMID:17460754
May be involved in the uptake and disposition of cationic compounds by renal clearance from the blood flow .
PMID:10966924
May contribute to regulate the transport of cationic compounds in testis across the blood-testis-barrier (Probable). Mediates the transport of polyamine spermidine and putrescine (By similarity). Mediates the bidirectional transport of polyamine agmatine .
PMID:12538837
Also transports guanidine .
PMID:10966924
May also mediate intracellular transport of organic cations, thereby playing a role in amine metabolism and intracellular signaling (By similarity)

Organic cation/carnitine transporter 2

BE0000106

SLC22A5

inhibitor

Specific function(R)-carnitine transmembrane transporter activity

Cellular location

Cell membrane

General function & pharmacology

Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine .
PMID:10454528 PMID:10525100 PMID:10966938 PMID:17509700 PMID:20722056 PMID:33124720

Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium.

Relative uptake activity ratio of carnitine to TEA is 11.3 .
PMID:10454528 PMID:10525100 PMID:10966938

In intestinal epithelia, transports the quorum-sensing pentapeptide CSF (competence and sporulation factor) from B.subtilis which induces cytoprotective heat shock proteins contributing to intestinal homeostasis .
PMID:18005709
May also contribute to regulate the transport of organic compounds in testis across the blood-testis-barrier (Probable)

POU domain, class 5, transcription factor 1

BE0003665

POU5F1

substrate

Specific functionDNA binding

Cellular location

Cytoplasm

General function & pharmacology

Transcription factor that binds to the octamer motif (5'-ATTTGCAT-3'). Forms a trimeric complex with SOX2 or SOX15 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206. Critical for early embryogenesis and for embryonic stem cell pluripotency

Biological pathways(64)

Catecholamine Biosynthesis

metabolic

Involved compounds

Dopamine,Epinephrine,Iron,Tyrosine,Levodopa,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Ascorbic acid

Aromatic L-Aminoacid Decarboxylase Deficiency

disease

Involved compounds

Dopamine,Epinephrine,Iron,Tyrosine,Levodopa,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Ascorbic acid

Dopamine Activation of Neurological Reward System

signaling

Involved compounds

ATP,Cyclic adenosine monophosphate,Pyrophosphoric acid,Dopamine,Magnesium cation

Benzocaine Action Pathway

Involved compounds

ATP,Benzocaine,Calcium,Dopamine,Norepinephrine,Potassium cation

Bupivacaine Action Pathway

Involved compounds

ATP,Bupivacaine,Calcium,Dopamine,Norepinephrine,Potassium cation

Chloroprocaine Action Pathway

Involved compounds

ATP,Calcium,Chloroprocaine,Dopamine,Norepinephrine,Potassium cation

Cocaine Action Pathway

Involved compounds

ATP,Calcium,Cocaine,Dopamine,Norepinephrine,Potassium cation

Dibucaine Action Pathway

Involved compounds

ATP,Calcium,Cinchocaine,Dopamine,Norepinephrine,Potassium cation

Levobupivacaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Levobupivacaine,Norepinephrine,Potassium cation

Lidocaine (Local Anaesthetic) Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Formaldehyde,Lidocaine,Mesoheme,NADH,Norepinephrine,Potassium cation

Mepivacaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Mepivacaine,Norepinephrine,Potassium cation

Oxybuprocaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Oxybuprocaine,Potassium cation

Prilocaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Prilocaine

Procaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Procaine

Proparacaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Proparacaine

Ropivacaine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Ropivacaine

Codeine Action Pathway

Involved compounds

ATP,Calcium,Codeine,Dopamine,Formaldehyde,Mesoheme,Morphine,NADH,Norepinephrine,Potassium cation,Uridine-5'-Diphosphate

Morphine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Morphine,Norepinephrine,Potassium cation,Uridine-5'-Diphosphate

Heroin Action Pathway

Involved compounds

Acetic acid,ATP,Calcium,Dopamine,Diamorphine,Morphine,Norepinephrine,Potassium cation

Methadone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Formaldehyde,Mesoheme,Methadone,NADH,Norepinephrine,Potassium cation

Oxycodone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Oxycodone,Potassium cation

Hydromorphone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Hydromorphone,Norepinephrine,Potassium cation

Hydrocodone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Hydrocodone,Norepinephrine,Potassium cation

Oxymorphone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Oxymorphone,Potassium cation

Alfentanil Action Pathway

Involved compounds

ATP,Alfentanil,Calcium,Dopamine,Norepinephrine,Potassium cation

Carfentanil Action Pathway

Involved compounds

ATP,Calcium,Carfentanil,Dopamine,Norepinephrine,Potassium cation

Fentanyl Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Fentanyl,Norepinephrine,Potassium cation

Remifentanil Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Remifentanil

Sufentanil Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Sufentanil

Imipramine Action Pathway

Involved compounds

ATP,Calcium,Desipramine,Dopamine,Formaldehyde,Imipramine,Mesoheme,NADH,Norepinephrine,Potassium cation

Desipramine Action Pathway

Involved compounds

ATP,Calcium,Desipramine,Dopamine,Mesoheme,Norepinephrine,Potassium cation

Citalopram Action Pathway

Involved compounds

ATP,Calcium,Citalopram,Dopamine,Flavin adenine dinucleotide,Formaldehyde,Mesoheme,Methylamine,NADH,Norepinephrine,Potassium cation

Escitalopram Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Escitalopram,Norepinephrine,Potassium cation

Fluoxetine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Fluoxetine,Formaldehyde,Mesoheme,NADH,Norepinephrine,Potassium cation,Seproxetine

Nicotine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Flavin adenine dinucleotide,Formaldehyde,Mesoheme,NADH,Nicotine,Norepinephrine,Potassium cation,Uridine-5'-Diphosphate

Tyrosine Hydroxylase Deficiency

disease

Involved compounds

Dopamine,Epinephrine,Iron,Tyrosine,Levodopa,Norepinephrine,Pyridoxal phosphate,Pyrroloquinoline Quinone,Ademetionine,Ascorbic acid

Tramadol Action Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Potassium cation,Tramadol

Propoxyphene Action Pathway

Involved compounds

ATP,Calcium,Dextropropoxyphene,Dopamine,Norepinephrine,Potassium cation

Levorphanol Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Levorphanol,Norepinephrine,Potassium cation

Anileridine Action Pathway

Involved compounds

ATP,Anileridine,Calcium,Dopamine,Norepinephrine,Potassium cation

Diphenoxylate Action Pathway

Involved compounds

ATP,Calcium,Diphenoxylate,Dopamine,Norepinephrine,Potassium cation

Dezocine Action Pathway

Involved compounds

ATP,Calcium,Dezocine,Dopamine,Norepinephrine,Potassium cation

Levomethadyl Acetate Action Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Levacetylmethadol,Norepinephrine,Potassium cation

Methadyl Acetate Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Methadyl acetate,Norepinephrine,Potassium cation

3-Methylthiofentanyl Action Pathway

Involved compounds

3-Methylthiofentanyl,ATP,Calcium,Dopamine,Norepinephrine,Potassium cation

Dimethylthiambutene Action Pathway

Involved compounds

ATP,Calcium,Dimethylthiambutene,Dopamine,Norepinephrine,Potassium cation

Ethylmorphine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Ethylmorphine,Norepinephrine,Potassium cation

Levallorphan Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Levallorphan,Norepinephrine,Potassium cation

Buprenorphine Action Pathway

Involved compounds

ATP,Buprenorphine,Calcium,Dopamine,Norepinephrine,Potassium cation

Alvimopan Action Pathway

Involved compounds

ATP,Alvimopan,Calcium,Dopamine,Norepinephrine,Potassium cation

Pentazocine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Norepinephrine,Pentazocine,Potassium cation

Naltrexone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Naltrexone,Norepinephrine,Potassium cation

Naloxone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Naloxone,Norepinephrine,Potassium cation

Dihydromorphine Action Pathway

Involved compounds

ATP,Calcium,Dihydromorphine,Dopamine,Norepinephrine,Potassium cation

Ketobemidone Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Ketobemidone,Norepinephrine,Potassium cation

Nalbuphine Action Pathway

Involved compounds

ATP,Calcium,Dopamine,Nalbuphine,Norepinephrine,Potassium cation

Scientific references(5)

Barron A.B., Maleszka R., Vander Meer R.K., Robinson G.E.

Octopamine modulates honey bee dance behavior.

Proceedings of the National Academy of Sciences

2007104(5):1703-1707. doi: 10.1073/pnas.0610506104

PMID: 17237217 DOI: 10.1073/pnas.0610506104

Giuliano F., Allard J.

Dopamine and Male Sexual Function.

European Urology

200140(6):601-608. doi: 10.1159/000049844

PMID: 11805404 DOI: 10.1159/000049844

Giuliano F., Allard J.

Dopamine and sexual function.

International Journal of Impotence Research

200113:S18-S28. doi: 10.1038/sj/ijir/3900719

PMID: 11477488 DOI: 10.1038/sj/ijir/3900719

Berridge K.C., Robinson T.E.

What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?.

Brain Research Reviews

199828(3):309-369. doi: 10.1016/s0165-0173(98)00019-8

PMID: 9858756 DOI: 10.1016/s0165-0173(98)00019-8

Pecina S., Cagniard B., Berridge K.C., Aldridge J.W., Zhuang X.

Hyperdopaminergic Mutant Mice Have Higher “Wanting” But Not “Liking” for Sweet Rewards.

The Journal of Neuroscience

200323(28):9395-9402. doi: 10.1523/jneurosci.23-28-09395.2003

PMID: 14561867 DOI: 10.1523/jneurosci.23-28-09395.2003

ATC classification(1 code)

ATC C01CA04

Affected organisms(1)

Humans and other mammals

International brands(2)

Salt forms(1)

Dopamine hydrochloride(DBSALT000508)

Experimental properties(6)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(33)

Commercial products(59)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Dopamine

DB00988

CAS number

51-61-6

UNII (FDA)

VTD58H1Z2X

InChI Key (molecular fingerprint)

VYFYYTLLBUKUHU-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

2322

ChEBI

18243

PubChem Compound

681

PubChem Substance

46506043

KEGG Compound

C03758

KEGG Drug

D07870

ChemSpider

661

BindingDB

55121

PharmGKB

PA449396

PDB

LDP

Therapeutic Targets Database

DAP000212

IUPHAR

940

Guide to Pharmacology

940

Wikipedia

Dopamine

ChEMBL

CHEMBL59

ZINC

ZINC000000033882

RxCUI

3628

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3023

GenAtlas

DRD2

GeneCards

DRD2

GenBank Gene Database

M30625

GenBank Protein Database

181432

IUPHAR

215

Guide to Pharmacology

215

UniProtKB

P14416

UniProt Accession

DRD2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3024

GenAtlas

DRD3

GeneCards

DRD3

GenBank Gene Database

U32499

GenBank Protein Database

927342

IUPHAR

216

Guide to Pharmacology

216

UniProtKB

P35462

UniProt Accession

DRD3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3025

GenAtlas

DRD4

GeneCards

DRD4

GenBank Gene Database

L12398

GenBank Protein Database

291946

IUPHAR

217

Guide to Pharmacology

217

UniProtKB

P21917

UniProt Accession

DRD4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11049

GenAtlas

SLC6A3

GeneCards

SLC6A3

GenBank Gene Database

M96670

GenBank Protein Database

553260

Guide to Pharmacology

927

UniProtKB

Q01959

UniProt Accession

SC6A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2689

GenAtlas

DBH

GeneCards

DBH

GenBank Gene Database

X13255

GenBank Protein Database

30474

Guide to Pharmacology

2486

UniProtKB

P09172

UniProt Accession

DOPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5286

GenAtlas

HTR1A

GeneCards

HTR1A

GenBank Gene Database

M28269

GenBank Protein Database

189928

IUPHAR

Guide to Pharmacology

UniProtKB

P08908

UniProt Accession

5HT1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5302

GenAtlas

HTR7

GeneCards

HTR7

GenBank Gene Database

U68487

GenBank Protein Database

1857143

IUPHAR

Guide to Pharmacology

UniProtKB

P34969

UniProt Accession

5HT7R_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3020

GenAtlas

DRD1

GeneCards

DRD1

GenBank Gene Database

X55760

GenBank Protein Database

30397

IUPHAR

214

Guide to Pharmacology

214

UniProtKB

P21728

UniProt Accession

DRD1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:3026

GenAtlas

DRD5

GeneCards

DRD5

GenBank Gene Database

X58454

GenBank Protein Database

32049

IUPHAR

218

Guide to Pharmacology

218

UniProtKB

P21918

UniProt Accession

DRD5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11048

GenAtlas

SLC6A2

GeneCards

SLC6A2

GenBank Gene Database

M65105

GenBank Protein Database

189258

Guide to Pharmacology

926

UniProtKB

P23975

UniProt Accession

SC6A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11050

GenAtlas

SLC6A4

GeneCards

SLC6A4

GenBank Gene Database

X70697

GenBank Protein Database

36433

Guide to Pharmacology

928

UniProtKB

P31645

UniProt Accession

SC6A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5298

GeneCards

HTR3B

Guide to Pharmacology

374

UniProtKB

O95264

UniProt Accession

5HT3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11179

GenAtlas

SOD1

GeneCards

SOD1

GenBank Gene Database

L44139

UniProtKB

P00441

UniProt Accession

SODC_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10935

GenAtlas

SLC18A2

GeneCards

SLC18A2

GenBank Gene Database

L09118

GenBank Protein Database

292335

Guide to Pharmacology

1012

UniProtKB

Q05940

UniProt Accession

VMAT2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2689

GenAtlas

DBH

GeneCards

DBH

GenBank Gene Database

X13255

GenBank Protein Database

30474

Guide to Pharmacology

2486

UniProtKB

P09172

UniProt Accession

DOPO_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6833

GenAtlas

MAOA

GeneCards

MAOA

GenBank Gene Database

M68840

GenBank Protein Database

187353

Guide to Pharmacology

2489

UniProtKB

P21397

UniProt Accession

AOFA_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6834

GenAtlas

MAOB

GeneCards

MAOB

GenBank Gene Database

S62734

GenBank Protein Database

398415

Guide to Pharmacology

2490

UniProtKB

P27338

UniProt Accession

AOFB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2228

GenAtlas

COMT

GeneCards

COMT

GenBank Gene Database

M65212

GenBank Protein Database

180920

Guide to Pharmacology

2472

UniProtKB

P21964

UniProt Accession

COMT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10966

GeneCards

SLC22A2

GenBank Gene Database

X98333

GenBank Protein Database

2281942

Guide to Pharmacology

1020

UniProtKB

O15244

UniProt Accession

S22A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10963

GeneCards

SLC22A1

GenBank Gene Database

X98332

GenBank Protein Database

2511670

Guide to Pharmacology

1019

UniProtKB

O15245

UniProt Accession

S22A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10967

GeneCards

SLC22A3

GenBank Gene Database

AJ001417

GenBank Protein Database

3581982

Guide to Pharmacology

1021

UniProtKB

O75751

UniProt Accession

S22A3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:10969

GenAtlas

SLC22A5

GeneCards

SLC22A5

GenBank Gene Database

AF057164

GenBank Protein Database

3273741

UniProtKB

O76082

UniProt Accession

S22A5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:9221

GeneCards

POU5F1

GenBank Gene Database

Z11898

GenBank Protein Database

35169

UniProtKB

Q01860

UniProt Accession

PO5F1_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.04/ml

To $0.15/ml

Dopamine 400 mg-d5w 250 ml

$0.04/ml

Dopamine 800 mg-d5w 500 ml

$0.05/ml

Dopamine 40 mg/ml vial

$0.15/ml

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Dopamine 200mg/50ml solution for infusion pre-filled syringes

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(13)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

International identifiers

Browse tools

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science
89

Chemical identifiers

Dopamine

Additional database identifiers

International reference pricing

DrugBank citations

Dopamine 200mg/50ml solution for infusion pre-filled syringes

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Medicines like this

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(13)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

International identifiers

Browse tools

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Half-life

Protein binding

Metabolism

Elimination

Clinical essentials

Pharmacology

Deep science89

Chemical identifiers

Dopamine

Additional database identifiers

International reference pricing

DrugBank citations

Deep science
89